Ieq Capital LLC Buys 5,171 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Ieq Capital LLC grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 307.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,852 shares of the biotechnology company’s stock after acquiring an additional 5,171 shares during the period. Ieq Capital LLC’s holdings in United Therapeutics were worth $2,418,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics during the 4th quarter valued at $25,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics during the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics in the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB lifted its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in United Therapeutics in the third quarter worth about $111,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 114,164 shares of company stock worth $41,671,293 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Down 1.7 %

Shares of United Therapeutics stock opened at $361.10 on Monday. The firm has a market cap of $16.12 billion, a PE ratio of 15.86, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $214.75 and a twelve month high of $417.82. The business has a 50-day moving average price of $362.68 and a 200 day moving average price of $360.72.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent research reports. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.